Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

APG-3288

Small molecule (PROTAC degrader) · Degrader of Bruton's tyrosine kinase (BTK) · developed by Ascentage Pharma Group

Phase 1 Most advanced trial
AAPG Developer
1 Registered trials

What is APG-3288?

APG-3288 is an orally bioavailable PROTAC that targets and degrades Bruton's tyrosine kinase (BTK) by recruiting cereblon to form a ternary complex, leading to proteasome-mediated BTK degradation. It blocks BTK/B-cell antigen receptor signaling and inhibits growth of malignant B-cells. It is studied in relapsed/refractory B-cell lymphomas and chronic lymphocytic leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule (PROTAC degrader)
Targets
Bruton's tyrosine kinase (BTK), cereblon (CRBN) (binding partner it blocks)
Mechanism
Degrader of Bruton's tyrosine kinase (BTK)
Pathways
BTK/BCR signaling, proteasome-mediated degradation
Therapy area
Oncology
Developer
Ascentage Pharma Group Inc. (AAPG)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07424833 Phase 1 Relapsed/Refractory Hematological Malignancies Recruiting AAPG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Relapsed/Refractory Follicular Lymphoma (FL)Relapsed/Refractory Hematological MalignanciesRelapsed/Refractory Mantle Cell Lymphoma (MCL)Relapsed/Refractory Marginal Zone Lymphoma (MZL)Relapsed/Refractory Waldenström Macroglobulinemia (WM)

Other drugs acting on BTK

Acalabrutinib FDA approved Pirtobrutinib FDA approved Zanubrutinib FDA approved

More from Ascentage Pharma Group

Alrizomadlin Phase 1/2 APG-2449 Phase 1 APG-5918 Phase 1 Dasminapant Phase 1/2 Lisaftoclax Phase 3 Olverembatinib Phase 3 Pelcitoclax Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AAPG page.

Follow AAPG, the company behind APG-3288

See AAPG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AAPG catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.